(Beyond Pesticides, October 8, 2024) A comprehensive literature review in Endocrines, published in September, amasses hundreds of studies on endocrine-disrupting chemicals (EDCs) that showcase adverse ...
A groundbreaking study jointly led by the School of Clinical Medicine at the LKS Faculty of Medicine, of the University of Hong Kong (HKUMed), has found that surgical removal of the diseased ...
In a recent study published in Hypertension Research, scientists examine the endocrine causes of hypertension (HTN) and investigate the efficacy of treatments to alleviate HTN. Study: Endocrine causes ...
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: ...
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months After a median follow-up of 6.6 ...
Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. We conducted a ...
Primary feasibility goal surpassed – 95 percent of participants (19/20) completed at least 75 percent of planned dosing, far exceeding the predefined 75 percent threshold. Early anti‑proliferative ...
In a previous post, I discussed the connection between the mind and the skin. In that article, I called for patients and clinicians to become more aware of the relationship between cutaneous and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback